
Katalognummer: 519 - RC1014
Produktkategori: Företag och industri > Vetenskap och laboratorium
Storlek: 1 Vial, Each vial contains 2 ~ 3 x 10^6 cells in 1 ml of 90% FBS + 10% DMSO.
| Storage and shipping | Immediately upon receipt, store in liquid nitrogen. |
|---|
RC1014
The STAT3 Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter under the transcriptional control of the STAT3 responsive promoter, so that the cell line is designed to measure the transcriptional activity of STAT3. As a transcription factor, Signal Transducer and Activator of Transcription 3 (STAT3) is activated through phosphorylation at tyrosine 705 in response to various cytokines including IL-6, interferons, epidermal growth factor, hepatocyte growth factor and leukemia inhibitory factor. The phosphorylated STAT3 forms homodimers or heterodimers with STAT1, and the dimers translocate to nucleus in which DNA binding/promoter induction occurs. The STAT3 induction by IL-6 is shown in Figure 1.
RC1040
The STAT4 Luciferase Reporter cell line is a stably transfected HEK 293 cell line which expresses Renilla luciferase reporter gene under the transcriptional control of the STAT4 responsive promoter, so that the cell line is designed to measure the transcriptional activity of STAT4. Signal Transducer and Activator of Transcription 4 (STAT4) is a member of the STAT transcription factor family and plays a central role in generating inflammation during protective immune responses and immune-mediated diseases. The STAT4 induction by interferon gamma is shown in Figure 1.
78498
The STAT3 Luciferase Reporter THP-1 cell line is designed for monitoring the STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene.
78325
Recombinant HEK293 cell line stably expressing full-length human Calcitonin receptor-like receptor (CALCRL/CRLR/CLR; accession number: NM_005795) and containing a firefly luciferase gene under the control of multimerized cAMP response element (CRE). This cell line can be used to measure the EC50 and IC50 of CALCRL agonists and antagonists using the luciferase reporter activity.
78547
The ADAR1 Luciferase Reporter HEK293 cell line is designed to monitor RNA editing by Adenosine deaminase acting on RNA (ADAR1). This cell line stably expresses ADAR1 under the control of a CMV promoter and a separate ADAR editing reporter construct expressed under the control of another CMV promoter. The reporter contains the gene encoding firefly luciferase, which is constitutively expressed in the cells, upstream of the gene encoding the GluA2 ADAR substrate followed by the Renilla luciferase gene. The sequence corresponding to GluA2 has been modified to contain an amber stop codon (UAG). When edited by ADAR, this stop codon (UAG) will be changed to UIG (A to I edit), which is read as tryptophan (UGG) by the translation machinery. This edit allows translation to occur all the way to the end of the reporter mRNA and results in the expression of Renilla luciferase. Conversely, in the absence of ADAR1 activity, translation terminates at the stop codon and Renilla is not expressed. Reporter activity is read out as the Renilla Luciferase/Firefly luciferase ratio whereby inhibition of ADAR activity, and thus the UAG (stop) to UGG (tryptophan) conversion rate, will result in a dose-dependent decrease in the Renilla luciferase/Firefly luciferase ratio.
78589
Recombinant HEK293 cells expressing the firefly luciferase gene under the control of cAMP response element (CRE), and with forced expression of human GIPR (Gastric Inhibitory Polypeptide receptor; NM_000164.4). Activation of GIPR in these cells can be monitored by measuring luciferase activity._x000D_The functionality of the GIPR/CRE Luciferase Reporter HEK293 Cell Line was validated in a dose-response assay using agonists gastric inhibitory peptide (GIP) and tirzepatide hydrochloride. These agonists induce luciferase activity in a dose-dependent manner as depicted in Figure 1._x000D_<p style="text-align: center;"><img src="{{media url="wysiwyg/Cell_Lines/78589.jpg"}}" alt="" width="530" height="301" />_x000D_Figure 1. Illustration of the GIPR/CRE Luciferase Reporter HEK293 Cell line.

By: Author , 2 Comment
12 mars 2026

By: Author , 2 Comment
3 mars 2026

By: Author , 2 Comment
30 januari 2026

By: Author , 2 Comment
12 mars 2026

